Partner Headlines - MDVN

  1. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD
  2. Consider Medivation for Your Portfolio

    FoxBusiness
  3. Benzinga's Top Downgrades

    Benzinga
  4. Goldman Sachs Downgrades Medivation To Neutral, Shares Drop

    Benzinga
  5. These 3 Biotech Stocks Just Hit New Highs

    Benzinga
  6. Fast Money Halftime Report Final Trade From September 12

    Benzinga
  7. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  8. Stifel Raises Medivation Inc Price Target

    Benzinga
  9. Stocks Hitting 52-Week Highs

    Benzinga
  10. A Few Reasons Why Investors Should Consider Dendreon for Their ...

    GuruFocus
  11. Medivation Cancer Drug Fuels Beat, Swings To Profit

    IBD
  12. Benzinga's Volume Movers

    Benzinga
  13. Medivation Announces Change in Executive Management Team; Dawn ...

    Benzinga
  14. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  15. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga
  16. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer ...

    Benzinga
  17. Benzinga's Top Upgrades

    Benzinga
  18. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga
  19. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as ...

    Benzinga
  20. Morning Market Movers

    Benzinga
  21. Stocks To Watch For April 1, 2014

    Benzinga
  22. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, ...

    Benzinga
  23. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® ...

    Benzinga
  24. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  25. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga
  26. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  27. Benzinga's Top #PreMarket Losers

    Benzinga
  28. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts
  29. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga
  30. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro ...

    Benzinga
  31. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  32. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts ...

    Benzinga
  33. Stocks Hitting 52-Week Highs

    Benzinga
  34. Benzinga's Top #PreMarket Gainers

    Benzinga
  35. Medivation and Astellas Announce Final Results From the Phase ...

    Benzinga
  36. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line ...

    Benzinga
  37. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide ...

    Benzinga
  38. Uh Oh: Is This Cancer Highflyer In Your Account?

    YCharts
  39. Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; ...

    Benzinga
  40. Medivation Elects Kathryn Falberg to Board of Directors

    Benzinga
  41. Medivation Bulls Load Up on Call Options

    SchaeffersResearch
  42. Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

    Benzinga
  43. Medivation, Inc. (MDVN) President and CEO David Hung sells 1 ...

    GuruFocus
  44. Benzinga's Top Initiations

    Benzinga
  45. Celgene, Regeneron Pharmaceutical Lead Biomed Group

    IBD
  46. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  47. UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

    Benzinga
  48. Medivation Effects 2-for-1 Stock Split

    Benzinga
  49. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga
  50. US FDA Approves XTANDI for Patients With Metastatic Castration-Resistant ...

    Benzinga
  51. Medivation Reports 2-for-1 Forward Split of Common Stock

    Benzinga
  52. Andreas Halvorsen Buys 2 Million Shares of Medivation

    GuruFocus
  53. Medivation Inc. (MDVN) President and CEO David Hung sells 25, ...

    GuruFocus
  54. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  55. Stocks Hitting 52-Week Highs

    Benzinga
  56. Health Care Sector Wrap

    FoxBusiness
  57. Four Winning Trades Based on Analyst Calls

    Benzinga
  58. Medivation Bull Looks to Cash In on Continued Rally

    SchaeffersResearch
  59. Analyst Upgrades: MDVN, SCHN, and STI

    SchaeffersResearch
  60. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  61. Citigroup Reiterates Buy Rating, $129 PT for Medivation

    Benzinga
  62. Medivation and Astellas Announce Enzalutamide Data

    Benzinga
  63. Crazy Action in Medivation After Negative StreetSweeper Post

    Benzinga
  64. Global Fears and Small Caps: How Much of an Impact?

    Benzinga
  65. Social Media Outlook for Tuesday 15 (DKS, MDVN, BBY, ACOM)

    Benzinga
  66. GlaxoSmithKline, Vertex Point To Biotech Strength

    IBD
  67. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  68. Will Johnson & Johnson Cure Cancer?

    Benzinga
  69. Options Players Show a Preference for Medivation Puts

    SchaeffersResearch
  70. Notable Put Options Activity in Medivation

    Benzinga
  71. Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, ...

    GuruFocus
  72. Medivation's Stellar Technical Performance Entices Option Bulls

    SchaeffersResearch
  73. Benzinga's M&A Chatter for Wednesday February 1, 2012

    Benzinga
  74. Medivation Soars on Phase III Trial Data; Stock Up 21%

    Benzinga
  75. Jefferies Raises PT on Medivation to $95

    Benzinga
  76. Wedbush Raises PT on Medivation to $81

    Benzinga
  77. Medivation and Astellas Announce Positive Results From the Phase ...

    Benzinga
  78. Upgrades & Downgrades: AZO, MDVN, POT, TSLA, and UA

    SchaeffersResearch
  79. Gilead, Celgene Join Big Pharma On M&A Front

    IBD
  80. Alzheimer's drug test halted

    IBD
  81. Best Biotech Stocks of 2011

    Benzinga
  82. Options Players Get Bearish with Medivation Puts

    SchaeffersResearch
  83. Notable Put Options Activity in Medivation

    Benzinga
  84. Put Volume Heats Up as Medivation Surges to a New High

    SchaeffersResearch
Trading Center